Voretigene neparvovec-rzyl

Dr. Mali's top 5 predictions in ophthalmology for 2018
Dr. Mali's top 5 predictions in ophthalmology for 2018Josh Mali, MD, shares his predictions for the 2018 ophthalmic year.
FDA approval of retinal dystrophy drug launches era of ocular gene therapyVoretigene neparvovec-rzyl (Luxturna, Spark Therapeutics) was approved in December 2017 for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Clinical trial results and patient selection issues for this gene therapy are discussed.